[go: up one dir, main page]

HUP9802795A2 - Elhízás kezelésére alkalmas, béta-adrenerg ágenst és étvágycsökkentő hatású vegyületet tartalmazó gyógyászati készítmények - Google Patents

Elhízás kezelésére alkalmas, béta-adrenerg ágenst és étvágycsökkentő hatású vegyületet tartalmazó gyógyászati készítmények

Info

Publication number
HUP9802795A2
HUP9802795A2 HU9802795A HUP9802795A HUP9802795A2 HU P9802795 A2 HUP9802795 A2 HU P9802795A2 HU 9802795 A HU9802795 A HU 9802795A HU P9802795 A HUP9802795 A HU P9802795A HU P9802795 A2 HUP9802795 A2 HU P9802795A2
Authority
HU
Hungary
Prior art keywords
agent
corpulence
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU9802795A
Other languages
English (en)
Inventor
Robert Lee Dow
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU9802795D0 publication Critical patent/HU9802795D0/hu
Publication of HUP9802795A2 publication Critical patent/HUP9802795A2/hu
Publication of HUP9802795A3 publication Critical patent/HUP9802795A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány őlyan gyógyászati készítményekre vőnatkőzik, amelyekegyrészt egy, az étkezési magatartást módősító vegyületet, ennekprődrűgját vagy ennek gyógyászatilag elfőgadható sóját vagy az űtóbbiprődrűgját, másrészt (4-(2-(2-(6-aminő-piridin-3-il)-2(R)-hidrőxi-etil-aminő)-etőxi)-fenil)-ecetsavat, ennek prődrűgját vagy az említett(4-(2-(2-(6-aminő-piridin-3-il)-2(R)-hidrőxi-etil-aminő)-etőxi)-fenil)-ecet- sav gyógyászatilag elfőgadható sóját vagy az űtóbbiprődrűgját tartalmazzák. A találmány szerinti gyógyászati készítményekelhízás és diabétesz kezelésére hasznősíthatók. ŕ
HU9802795A 1997-12-03 1998-12-02 Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence HUP9802795A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6726897P 1997-12-03 1997-12-03

Publications (3)

Publication Number Publication Date
HU9802795D0 HU9802795D0 (en) 1999-01-28
HUP9802795A2 true HUP9802795A2 (hu) 1999-08-30
HUP9802795A3 HUP9802795A3 (en) 2000-01-28

Family

ID=22074866

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802795A HUP9802795A3 (en) 1997-12-03 1998-12-02 Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence

Country Status (7)

Country Link
EP (1) EP0920864A1 (hu)
JP (1) JPH11228447A (hu)
KR (1) KR19990062718A (hu)
AU (1) AU9605598A (hu)
CA (1) CA2255318A1 (hu)
HU (1) HUP9802795A3 (hu)
IL (1) IL127306A0 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0858340A4 (en) * 1995-11-01 1999-12-29 Merck & Co Inc COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY
US6246876B1 (en) 1997-11-13 2001-06-12 Telefonaktiebolaget L M Ericsson (Publ) Synchronization messages for hand-off operations
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
CA2362070A1 (en) 1999-02-16 2000-08-24 Masaru Mitsuda Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active .beta.3 agonist by the use of the same
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
MXPA04002751A (es) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modificacion del comportamiento de alimentacion.
EP1474163A2 (en) * 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2007139062A1 (ja) * 2006-05-30 2007-12-06 Kyorin Pharmaceutical Co., Ltd. 肥満治療剤並びに肥満の治療及び予防方法
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
JP6253451B2 (ja) 2014-02-05 2017-12-27 学校法人自治医科大学 満腹感持続剤および満足感を維持する方法
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
LT3393655T (lt) 2015-12-22 2021-03-25 Zogenix International Limited Fenfluramino kompozicijos ir jų paruošimo būdai
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504648A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作動性アゴニスト
CA2220399A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
EP0858340A4 (en) * 1995-11-01 1999-12-29 Merck & Co Inc COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY

Also Published As

Publication number Publication date
EP0920864A1 (en) 1999-06-09
KR19990062718A (ko) 1999-07-26
CA2255318A1 (en) 1999-06-03
AU9605598A (en) 1999-06-24
JPH11228447A (ja) 1999-08-24
HUP9802795A3 (en) 2000-01-28
HU9802795D0 (en) 1999-01-28
IL127306A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
HUP9802795A2 (hu) Elhízás kezelésére alkalmas, béta-adrenerg ágenst és étvágycsökkentő hatású vegyületet tartalmazó gyógyászati készítmények
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
SE9500422D0 (sv) New oral pharmaceutical dosage forms
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
RU99118887A (ru) Применение ингибиторов желудочно-кишечной липазы
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
CA2028746A1 (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
ME00578A (en) Use of gastrointestinal lipase inhibitors
DE69628415D1 (de) Arzneimittel enthaltend monoaminooxidase-b-hemmer
EP1295609A4 (en) MEDICINES WITH MIXED ACTIVE SUBSTANCES
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
AU1812395A (en) Film coated tablet of paracetamol and domperidone
ATE173923T1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
WO2002007721A3 (en) Use of cox-2 inhibitors for preventing immunodeficiency
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
DK1408966T3 (da) Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
EP1797897A4 (en) MEDICAL COMPOSITION WITH A MELTRINE ANTAGONIST